Company Profile

Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. It also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. It uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.

Employees

460

Sector

Software

More about the company

07-21	PatientsLikeMe and Science 37 Announce Strategic Partnership To Accelerate Clinical Trial Enrollment and Expand Access	CI
03-17	Science 37 Launches Dedicated Pediatrics Department to Expand Access to Specialized Clinical Research for Children and Families	CI
25-10-08	Science 37 Completes Third Fda Inspection, Validating Quality of Its Direct-To-Patient Site in Pivotal Phase 3 Rare Disease Trial	CI
25-04-08	Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial	CI
25-01-14	Science 37 Announces Appointment of Tyler Van Horn as Chief Executive Officer	CI
24-08-06	Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC	CI
24-06-12	Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial	CI
24-05-13	Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance	CI
24-05-02	Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial	CI
24-03-11	Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index	CI
24-03-11	Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from S&P TMI Index	CI
24-03-10	EMed, LLC completed the acquisition of Science 37 Holdings, Inc..	CI
24-01-30	Baird Downgrades Science 37 Holdings to Neutral From Outperform, Price Target is $5.75	MT

24-01-30	Baird Downgrades Science 37 Holdings to Neutral From Outperform, Price Target is $5.75	MT
24-01-29	Baird Adjusts Science 37 Holdings' Price Target to $5.75 From $15, Keeps Outperform Rating	MT
24-01-29	Craig-Hallum Downgrades Science 37 Holdings to Hold From Buy	MT
23-03-07	Baird Adjusts Science 37 Holdings Price Target to $1 From $2, Maintains Outperform Rating	MT
22-11-14	William Blair Downgrades Science 37 Holdings to Market Perform From Outperform	MT

24-07-18	Science 37 : Enrolls 42% of Trial Cohort in 8 Weeks	PU
24-06-12	Science 37 : Surpasses Enrollment Goals,…	PU
24-05-13	Science 37 : Metasite™ Undergoes Successful FDA…	PU
24-05-02	Science 37 : Delivers 22x Faster Enrollment than…	PU
24-03-12	EMed completes tender offer for all outstanding shares of Science 37	PR

Manager	Title	Age	Since
Tyler Van Horn CEO	Chief Executive Officer	-	2025-01-13
Mike Zaranek DFI	Director of Finance/CFO	54	2021-10-05
Irena Lambridis CMP	Compliance Officer	-	2023-04-17

Director	Title	Age	Since
Jeffrey Schumm BRD	Director/Board Member	64	2024-03-11
Michael Cole BRD	Director/Board Member	53	2024-03-11

Science 37 Holdings, Inc. Stock

Stocks

SNCE

US8086442071

Software

Latest news: Science 37 Holdings, Inc.

Analysts' recommendations: Science 37 Holdings, Inc.

Press Releases: Science 37 Holdings, Inc.

Quotes and Performance

Managers and Directors: Science 37 Holdings, Inc.

Latest insider transactions

Other Software

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/12/24	Jonathan Cotliar	Tender	Chief Technology Officer	91,172	1.5124%
3/12/24	Emily Rollins	Tender	Director	28,170	0.4673%
3/12/24	Redmile Group LLC	Tender	Company	1,115,036	18.4971%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENCE 37 HOLDINGS, INC.	+0.35%	+0.35%	-	-	34.67M
MICROSOFT CORPORATION	-1.37%	-0.27%	-3.68%	+48.48%	3,691B
PALANTIR TECHNOLOGIES INC.	+1.03%	+2.84%	+2.40%	+1,037.25%	415B
DATADOG, INC.	+0.23%	+2.45%	+71.48%	+144.09%	82.68B
CADENCE DESIGN SYSTEMS, INC.	+2.17%	-1.65%	-19.80%	+19.57%	75.45B
SYNOPSYS, INC.	+2.93%	-3.75%	-11.15%	-16.25%	70.46B
SEA LIMITED	+0.83%	-4.79%	-45.26%	+163.49%	62.87B
ATLASSIAN CORPORATION	+0.25%	+7.06%	+10.60%	-6.28%	48.05B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-0.05%	+0.32%	-14.50%	+48.21%	39.62B
TWILIO INC.	-1.35%	+5.15%	+133.94%	+280.87%	37.19B
Average	+0.48%	+0.46%	+13.78%	+191.05%	502.49B
Weighted average by Cap.	+0.27%	+0.74%	-1.52%	+142.32%